Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
Saved in:
| Title: | Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. |
|---|---|
| Authors: | Salvi, S1, Casadio, V1, Conteduca, V2, Burgio, S L2, Menna, C2, Bianchi, E2, Rossi, L2, Carretta, E3, Masini, C4, Amadori, D2, Calistri, D1, Attard, G5, De Giorgi, U2 |
| Source: | British Journal of Cancer. 5/12/2015, Vol. 112 Issue 10, p1717-1724. 8p. 2 Charts, 3 Graphs. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
